Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Neutral 0

Boston Scientific (BSX) Stock Sinks As Market Gains: Here's Why

AI-generated analysis

πŸ“‰ Boston Scientific (BSX) stock closed at $61.86, down 1.17%, trailing the S&P 500's gain and outperforming the Dow and Nasdaq mixed performance.

πŸ₯ Over the past month, BSX shares have dropped 12.95%, which is a sharper decline than the Medical sector and the broader S&P 500 losses.

πŸ“… Investors are anticipating the upcoming earnings report scheduled for April 22, 2026, with consensus estimates predicting an EPS of $0.8.

πŸ“ˆ Analyst forecasts suggest quarterly revenue will reach $5.19 billion, representing an 11.2% increase compared to the prior-year quarter.

πŸ” The annual forecast predicts earnings per share of $3.45 and revenue of $22.28 billion, with positive growth of 12.75% and 10.99% respectively.

βš–οΈ Boston Scientific is currently trading at a Forward P/E ratio of 18.13, which is slightly below its industry average of 18.15.

πŸ“Š The company has a PEG ratio of 0.97 compared to the Medical Products industry average of 1.59, suggesting a potentially attractive valuation relative to growth.

πŸ₯‡ BSX holds a Zacks Rank of #3 (Hold), while the recent trend shows a slight 0.15% fall in the consensus EPS estimate over the past month.

πŸ“Š The Medical - Products industry is ranked in the bottom 34% of all industries with a Zacks Industry Rank of 163 out of over 250 sectors.

πŸ’‘ Zacks Investment Research notes that top-rated industries historically outperform bottom-tier groups by a factor of 2 to 1 based on research data.

Bullish Signals
  • The company is expected to post an EPS of $0.8, indicating 6.67% growth compared to the equivalent quarter last year.
  • Analysts are forecasting annual revenue of $22.28 billion, representing a 10.99% increase from the prior year.
  • Boston Scientific is trading at a Forward P/E ratio of 18.13, which is slightly below the industry average of 18.15, indicating a valuation discount.
  • The company's PEG ratio is 0.97, suggesting it is trading close to its expected earnings growth rate compared to the industry average of 1.59.
  • With an estimated upcoming revenue of $5.19 billion in the current quarter, Boston Scientific anticipates year-over-year growth of 11.2%.
Risk Factors
  • Boston Scientific's stock has dropped by 12.95% in the past month, significantly underperforming both the Medical sector's loss of 6.98% and the S&P 500's loss of 1.74%.
  • The company's Zacks Rank is #3 (Hold), which indicates neutral to negative sentiment compared to top-ranked stocks that deliver an average annual return of +25% since 1988.
  • The Medical - Products industry ranks in the bottom 34% of all industries according to its Zacks Industry Rank, with top-rated industries outperforming the bottom half by a factor of 2 to 1.
  • Boston Scientific's PEG ratio of 0.97 is significantly lower than the industry average PEG ratio of 1.59, potentially suggesting overvaluation relative to growth expectations or market skepticism.
  • Over the past month, there has been a 0.15% fall in the Zacks Consensus EPS estimate, indicating declining analyst confidence despite predicted earnings growth.
Full Analysis
Boston Scientific stock closed at $61.86, marking a 1.17% decline that lagged the broader S&P 500's modest 0.08% gain despite market fluctuations where the Dow lost 0.18% and Nasdaq rose 0.1%. The company has experienced a more pronounced 12.95% drop over the past month, significantly underperforming both the medical device sector, which fell 6.98%, and the overall S&P 500, which dropped 1.74% during the same period. Investors are closely monitoring the company ahead of its upcoming earnings disclosure scheduled for April 22, 2026, where analysts project an earnings per share of $0.8, representing a 6.67% growth over the equivalent quarter last year, and revenue estimates of $5.19 billion, an 11.2% increase from the prior-year quarter. For the full fiscal year, Zacks Consensus Estimates anticipate Boston Scientific will report earnings of $3.45 per share and total revenue of $22.28 billion, reflecting projected growth rates of +12.75% and +10.99% respectively compared to the previous year. However, recent analyst estimate adjustments show a slight downward trend, with a 0.15% fall in the Zacks Consensus EPS estimate over the past month. Consequently, Boston Scientific currently holds a Zacks Rank of #3 (Hold). The article notes that while upward revisions often signal positive analyst sentiment and correlate with future stock price performance, the current data does not reflect such optimism. In terms of valuation metrics, the stock trades at a forward P/E ratio of 18.13, which is slightly below the industry average forward P/E of 18.15 for the medical products sector. Additionally, the company's PEG ratio stands at 0.97, significantly lower than the Medical - Products industry average of 1.59, suggesting the stock might be undervalued relative to its growth expectations compared to peers. The broader market context highlights that the Medical - Products industry ranks in the bottom 34% of all industries according to the Zacks Industry Rank, which currently stands at 163 out of over 250 groups. Research indicates that top-performing industries tend to outperform the bottom half by a factor of 2 to 1, adding further context to Boston Scientific's recent performance. While the Zacks Rank #1 (Strong Buy) category has historically delivered an average annual return of +25% since 1988, Boston Scientific currently sits in a neutral holding zone. The article concludes by directing investors to utilize Zacks.com for real-time updates on these shifting metrics and suggests downloading their "7 Best Stocks for the Next 30 Days" report for additional investment recommendations.